Copper Binding by Tetrathiomolybdate Attenuates Angiogenesis and Tumor Cell Proliferation through the Inhibition of Superoxide Dismutase 1
Purpose: A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently completing two phase I clinical trials in patients with advanced solid and advanced hematologic malignancies. However, there is very little...
Saved in:
Published in | Clinical cancer research Vol. 12; no. 16; pp. 4974 - 4982 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
15.08.2006
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose: A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with
high affinity, is currently completing two phase I clinical trials in patients with advanced solid and advanced hematologic
malignancies. However, there is very little information about the mechanism of action of ATN-224 at the molecular level.
Experimental Design: The effects of ATN-224 on endothelial and tumor cell growth were evaluated in cell culture experiments in vitro . The antiangiogenic activity of ATN-224 was investigated using the Matrigel plug model of angiogenesis.
Results: ATN-224 inhibits superoxide dismutase 1 (SOD1) in tumor and endothelial cells. The inhibition of SOD1 leads to inhibition
of endothelial cell proliferation in vitro and attenuation of angiogenesis in vivo . The inhibition of SOD1 activity in endothelial cells is dose and time dependent and leads to an increase in the steady-state
levels of superoxide anions, resulting in the inhibition of extracellular signal-regulated kinase phosphorylation without
apparent induction of apoptosis. In contrast, the inhibition of SOD1 in tumor cells leads to the induction of apoptosis. The
effects of ATN-224 on endothelial and tumor cells could be substantially reversed using Mn(III)tetrakis(4-benzoic acid)porphyrin
chloride, a catalytic small-molecule SOD mimetic.
Conclusions: These data provide a distinct molecular target for the activity of ATN-224 and provide validation for SOD1 as a target for
the inhibition of angiogenesis and tumor growth. |
---|---|
AbstractList | Abstract
Purpose: A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently completing two phase I clinical trials in patients with advanced solid and advanced hematologic malignancies. However, there is very little information about the mechanism of action of ATN-224 at the molecular level.
Experimental Design: The effects of ATN-224 on endothelial and tumor cell growth were evaluated in cell culture experiments in vitro. The antiangiogenic activity of ATN-224 was investigated using the Matrigel plug model of angiogenesis.
Results: ATN-224 inhibits superoxide dismutase 1 (SOD1) in tumor and endothelial cells. The inhibition of SOD1 leads to inhibition of endothelial cell proliferation in vitro and attenuation of angiogenesis in vivo. The inhibition of SOD1 activity in endothelial cells is dose and time dependent and leads to an increase in the steady-state levels of superoxide anions, resulting in the inhibition of extracellular signal-regulated kinase phosphorylation without apparent induction of apoptosis. In contrast, the inhibition of SOD1 in tumor cells leads to the induction of apoptosis. The effects of ATN-224 on endothelial and tumor cells could be substantially reversed using Mn(III)tetrakis(4-benzoic acid)porphyrin chloride, a catalytic small-molecule SOD mimetic.
Conclusions: These data provide a distinct molecular target for the activity of ATN-224 and provide validation for SOD1 as a target for the inhibition of angiogenesis and tumor growth. Purpose: A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently completing two phase I clinical trials in patients with advanced solid and advanced hematologic malignancies. However, there is very little information about the mechanism of action of ATN-224 at the molecular level. Experimental Design: The effects of ATN-224 on endothelial and tumor cell growth were evaluated in cell culture experiments in vitro . The antiangiogenic activity of ATN-224 was investigated using the Matrigel plug model of angiogenesis. Results: ATN-224 inhibits superoxide dismutase 1 (SOD1) in tumor and endothelial cells. The inhibition of SOD1 leads to inhibition of endothelial cell proliferation in vitro and attenuation of angiogenesis in vivo . The inhibition of SOD1 activity in endothelial cells is dose and time dependent and leads to an increase in the steady-state levels of superoxide anions, resulting in the inhibition of extracellular signal-regulated kinase phosphorylation without apparent induction of apoptosis. In contrast, the inhibition of SOD1 in tumor cells leads to the induction of apoptosis. The effects of ATN-224 on endothelial and tumor cells could be substantially reversed using Mn(III)tetrakis(4-benzoic acid)porphyrin chloride, a catalytic small-molecule SOD mimetic. Conclusions: These data provide a distinct molecular target for the activity of ATN-224 and provide validation for SOD1 as a target for the inhibition of angiogenesis and tumor growth. A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently completing two phase I clinical trials in patients with advanced solid and advanced hematologic malignancies. However, there is very little information about the mechanism of action of ATN-224 at the molecular level. The effects of ATN-224 on endothelial and tumor cell growth were evaluated in cell culture experiments in vitro. The antiangiogenic activity of ATN-224 was investigated using the Matrigel plug model of angiogenesis. ATN-224 inhibits superoxide dismutase 1 (SOD1) in tumor and endothelial cells. The inhibition of SOD1 leads to inhibition of endothelial cell proliferation in vitro and attenuation of angiogenesis in vivo. The inhibition of SOD1 activity in endothelial cells is dose and time dependent and leads to an increase in the steady-state levels of superoxide anions, resulting in the inhibition of extracellular signal-regulated kinase phosphorylation without apparent induction of apoptosis. In contrast, the inhibition of SOD1 in tumor cells leads to the induction of apoptosis. The effects of ATN-224 on endothelial and tumor cells could be substantially reversed using Mn(III)tetrakis(4-benzoic acid)porphyrin chloride, a catalytic small-molecule SOD mimetic. These data provide a distinct molecular target for the activity of ATN-224 and provide validation for SOD1 as a target for the inhibition of angiogenesis and tumor growth. PURPOSEA second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently completing two phase I clinical trials in patients with advanced solid and advanced hematologic malignancies. However, there is very little information about the mechanism of action of ATN-224 at the molecular level.EXPERIMENTAL DESIGNThe effects of ATN-224 on endothelial and tumor cell growth were evaluated in cell culture experiments in vitro. The antiangiogenic activity of ATN-224 was investigated using the Matrigel plug model of angiogenesis.RESULTSATN-224 inhibits superoxide dismutase 1 (SOD1) in tumor and endothelial cells. The inhibition of SOD1 leads to inhibition of endothelial cell proliferation in vitro and attenuation of angiogenesis in vivo. The inhibition of SOD1 activity in endothelial cells is dose and time dependent and leads to an increase in the steady-state levels of superoxide anions, resulting in the inhibition of extracellular signal-regulated kinase phosphorylation without apparent induction of apoptosis. In contrast, the inhibition of SOD1 in tumor cells leads to the induction of apoptosis. The effects of ATN-224 on endothelial and tumor cells could be substantially reversed using Mn(III)tetrakis(4-benzoic acid)porphyrin chloride, a catalytic small-molecule SOD mimetic.CONCLUSIONSThese data provide a distinct molecular target for the activity of ATN-224 and provide validation for SOD1 as a target for the inhibition of angiogenesis and tumor growth. |
Author | Jose C. Juarez Oscar Betancourt, Jr Andrew P. Mazar Fernando Doñate Melissa L. Price David E. Shaw Xiaojun Guan Steven R. Pirie-Shepherd |
Author_xml | – sequence: 1 fullname: Jose C. Juarez – sequence: 2 fullname: Oscar Betancourt, Jr – sequence: 3 fullname: Steven R. Pirie-Shepherd – sequence: 4 fullname: Xiaojun Guan – sequence: 5 fullname: Melissa L. Price – sequence: 6 fullname: David E. Shaw – sequence: 7 fullname: Andrew P. Mazar – sequence: 8 fullname: Fernando Doñate |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18052150$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16914587$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkcuO1DAQRS00iHnAJ4C8AYlFBjvxI1k24TXSSCBo1pbjVBKjxG5sR9C_wFfj0I1mVSXr3KryvdfownkHCD2n5JZSXr-hRNYFYVV527ZfCyIKQiV9hK4o57KoSsEvcv-fuUTXMf4ghDJK2BN0SUVDGa_lFfrT-sMBAn5rXW_diLsj3kMKOk3WL34-dr1OgHcpgVtzF_HOjdaP4CDaiLXr8X5dfMAtzDP-EvxsB8hq6x1OU_DrOOUK-M5NtrP_nv2Av615pf9te8DvbFzWpCNg-hQ9HvQc4dm53qDvH97v20_F_eePd-3uvjCsblJRkqbU_cAYGN7UPZiayKHRtAdgtYaBC2qgrFgjiaCV6JrKECOklpXWtBxkdYNeneYegv-5QkxqsdHk-7UDv0YlaslFWW0gP4Em-BgDDOoQ7KLDUVGithDUZrDaDFY5BEWE2kLIuhfnBWu3QP-gOruegZdnQEej5yFoZ2x84GrCS8pJ5l6fuMmO0y8bQJlMQggQQQczKVrmoSp_lVV_AW5Eom8 |
CitedBy_id | crossref_primary_10_3389_fonc_2023_1209156 crossref_primary_10_3390_cancers2010165 crossref_primary_10_1016_j_jinorgbio_2012_07_003 crossref_primary_10_1093_annonc_mds654 crossref_primary_10_1136_vr_100722 crossref_primary_10_18632_oncotarget_4875 crossref_primary_10_3390_ijms21031069 crossref_primary_10_2174_1570164618666210728121529 crossref_primary_10_1016_j_jtemb_2014_07_015 crossref_primary_10_3892_ijo_2014_2396 crossref_primary_10_1074_jbc_R800055200 crossref_primary_10_1038_sj_bjc_6604226 crossref_primary_10_7554_eLife_91611 crossref_primary_10_1016_j_ccr_2020_213635 crossref_primary_10_1038_srep15911 crossref_primary_10_1016_j_freeradbiomed_2013_02_003 crossref_primary_10_1167_iovs_18_25999 crossref_primary_10_1038_s41467_021_22480_x crossref_primary_10_1158_1078_0432_CCR_08_0315 crossref_primary_10_1016_j_jtemb_2024_127436 crossref_primary_10_1002_dvdy_24285 crossref_primary_10_1124_mol_109_057430 crossref_primary_10_1016_j_ccr_2023_215395 crossref_primary_10_1186_1471_2407_10_375 crossref_primary_10_1016_j_pharmthera_2022_108109 crossref_primary_10_1016_j_mvr_2009_01_003 crossref_primary_10_1007_s00775_014_1107_8 crossref_primary_10_1073_pnas_1113554108 crossref_primary_10_1155_2019_9706792 crossref_primary_10_1093_conphys_coac025 crossref_primary_10_1371_journal_pone_0191607 crossref_primary_10_1038_sj_bjc_6604882 crossref_primary_10_1016_j_bbamcr_2020_118893 crossref_primary_10_1080_10934529_2011_532430 crossref_primary_10_7554_eLife_91611_3 crossref_primary_10_1073_pnas_1513433112 crossref_primary_10_1016_j_ygyno_2011_03_035 crossref_primary_10_1158_1541_7786_MCR_22_0056 crossref_primary_10_1007_s00775_015_1323_x crossref_primary_10_1021_tx900111y crossref_primary_10_1097_CMR_0b013e32832c6324 crossref_primary_10_1073_pnas_2023328119 crossref_primary_10_3390_molecules27010148 crossref_primary_10_1017_S0954422419000180 crossref_primary_10_1258_ebm_2011_011267 crossref_primary_10_1507_endocrj_K09E_051 crossref_primary_10_1158_1078_0432_CCR_06_2082 crossref_primary_10_1016_j_canlet_2023_216157 crossref_primary_10_2174_1381612826666200628022113 crossref_primary_10_3389_fonc_2023_1186659 crossref_primary_10_1186_1471_2407_10_9 crossref_primary_10_1080_15548627_2023_2200554 crossref_primary_10_3390_antiox11020427 crossref_primary_10_1159_000438485 crossref_primary_10_3389_fonc_2022_937444 crossref_primary_10_1021_jo1013564 crossref_primary_10_1039_c002439b crossref_primary_10_1126_science_1179907 crossref_primary_10_1007_s11356_015_5035_0 crossref_primary_10_1016_j_ijbiomac_2023_126684 crossref_primary_10_1016_j_redox_2020_101440 crossref_primary_10_1039_D2DT04060C crossref_primary_10_1073_pnas_0709451105 crossref_primary_10_1002_adtp_202300198 crossref_primary_10_1038_mto_2015_8 crossref_primary_10_1155_2013_704654 crossref_primary_10_1128_MCB_05722_11 crossref_primary_10_3390_antiox12061159 crossref_primary_10_3390_biomedicines9080852 crossref_primary_10_1158_1078_0432_CCR_17_3705 crossref_primary_10_1039_C5RA03210E crossref_primary_10_1089_ars_2009_2541 crossref_primary_10_1002_iub_2821 crossref_primary_10_1016_j_cbpa_2016_12_011 crossref_primary_10_3164_jcbn_11_15 crossref_primary_10_1080_10799890903208039 crossref_primary_10_1002_adtp_202000164 crossref_primary_10_1038_nrd2803 crossref_primary_10_1038_s41568_021_00417_2 crossref_primary_10_1038_scibx_2008_421 crossref_primary_10_1038_s41598_018_19873_2 crossref_primary_10_1165_rcmb_2011_0296OC crossref_primary_10_1158_1535_7163_MCT_18_0667 crossref_primary_10_1021_acsami_7b08347 crossref_primary_10_1016_j_neuroscience_2013_10_033 crossref_primary_10_1111_j_1365_2818_2010_03380_x crossref_primary_10_18632_oncotarget_23886 crossref_primary_10_1038_s41419_022_05267_w crossref_primary_10_1158_1078_0432_CCR_12_0697 crossref_primary_10_1016_j_drudis_2015_10_001 crossref_primary_10_1074_jbc_RA118_007095 crossref_primary_10_1534_genetics_113_156836 crossref_primary_10_4049_jimmunol_1700712 crossref_primary_10_1021_jacs_0c06379 crossref_primary_10_3945_an_112_002220 crossref_primary_10_1016_j_urolonc_2011_04_009 crossref_primary_10_1172_JCI71714 crossref_primary_10_1016_j_jcpa_2022_07_002 crossref_primary_10_1016_j_redox_2014_01_001 crossref_primary_10_1126_scisignal_2004870 crossref_primary_10_1371_journal_pone_0071982 crossref_primary_10_1007_s00280_008_0791_x crossref_primary_10_1002_adtp_201800147 crossref_primary_10_1039_C6SC01272H crossref_primary_10_1158_1535_7163_MCT_14_0420 crossref_primary_10_3390_biom12101520 crossref_primary_10_1042_BST20140087 crossref_primary_10_1016_j_biopha_2024_116874 crossref_primary_10_1016_j_pneurobio_2014_01_002 crossref_primary_10_1186_1471_2407_12_147 crossref_primary_10_1586_14737140_8_11_1751 crossref_primary_10_1016_j_etap_2017_12_022 crossref_primary_10_1021_jm301053a crossref_primary_10_1016_j_celrep_2022_110995 crossref_primary_10_1016_j_drup_2023_101018 |
Cites_doi | 10.1073/pnas.87.24.10028 10.1006/cbir.1997.0220 10.1016/S0021-9258(19)85312-7 10.1016/0022-1759(91)90327-C 10.1158/1535-7163.1049.3.9 10.1038/35030140 10.1006/abbi.1998.0618 10.1038/sj.neo.7900218 10.1002/ijc.1565 10.1016/S0891-5849(03)00142-4 10.1177/1534735402238185 10.1073/pnas.1231994100 10.1016/S0024-3205(98)00560-8 10.1038/nm0195-27 10.1152/jappl.1993.74.3.1425 10.1074/jbc.M307146200 10.1038/sj.bjc.6600078 10.1016/0162-0134(84)85008-4 10.1016/0162-0134(86)80011-3 10.1074/jbc.M107711200 10.2174/1568009053765807 10.1016/0014-4827(80)90051-8 10.1073/pnas.89.21.10405 10.1161/01.RES.85.2.147 |
ContentType | Journal Article |
Copyright | 2006 INIST-CNRS |
Copyright_xml | – notice: 2006 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1158/1078-0432.CCR-06-0171 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1557-3265 |
EndPage | 4982 |
ExternalDocumentID | 10_1158_1078_0432_CCR_06_0171 16914587 18052150 12_16_4974 |
Genre | Journal Article |
GroupedDBID | - 08R 29B 2WC 34G 39C 3O- 4H- 53G 55 5GY 5RE 5VS AAPBV ABFLS ABOCM ACIWK ACPRK ADACO ADBBV ADBIT AENEX AETEA AFFNX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL C1A CS3 DIK DU5 E3Z EBS EJD F5P FH7 FRP GJ GX1 H13 H~9 IH2 KQ8 L7B LSO MVM O0- OHT OK1 P0W P2P RCR RHF RHI RNS SJN UDS VH1 W2D WOQ X7M XFK XJT ZA5 ZCG ZGI --- .55 .GJ 18M 1CY 2FS 476 6J9 AAUGY ACGFO ACSVP ADCOW ADNWM AFHIN AFOSN AI. BR6 BTFSW IQODW J5H QTD TR2 W8F WHG YKV CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c489t-2092adf44ec598dec807f9a1dee48aef561ce2349706136b93c0c67a73aa12f73 |
ISSN | 1078-0432 |
IngestDate | Sat Aug 17 02:58:28 EDT 2024 Fri Aug 23 00:41:13 EDT 2024 Thu May 23 23:10:18 EDT 2024 Sun Oct 29 17:07:34 EDT 2023 Fri Jan 15 20:06:54 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 16 |
Keywords | Cell proliferation Angiogenesis Enzyme Superoxide dismutase Inhibitor Oxidoreductases Neovascularization Copper Tumor cell |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c489t-2092adf44ec598dec807f9a1dee48aef561ce2349706136b93c0c67a73aa12f73 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 16914587 |
PQID | 68756237 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_68756237 crossref_primary_10_1158_1078_0432_CCR_06_0171 pubmed_primary_16914587 pascalfrancis_primary_18052150 highwire_cancerresearch_12_16_4974 |
ProviderPackageCode | RHF RHI |
PublicationCentury | 2000 |
PublicationDate | 2006-08-15 |
PublicationDateYYYYMMDD | 2006-08-15 |
PublicationDate_xml | – month: 08 year: 2006 text: 2006-08-15 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | Philadelphia, PA |
PublicationPlace_xml | – name: Philadelphia, PA – name: United States |
PublicationTitle | Clinical cancer research |
PublicationTitleAlternate | Clin Cancer Res |
PublicationYear | 2006 |
Publisher | American Association for Cancer Research |
Publisher_xml | – name: American Association for Cancer Research |
References | 2022061105054262500_B10 2022061105054262500_B30 2022061105054262500_B17 2022061105054262500_B18 2022061105054262500_B15 2022061105054262500_B16 2022061105054262500_B13 2022061105054262500_B14 2022061105054262500_B11 2022061105054262500_B12 2022061105054262500_B19 2022061105054262500_B20 2022061105054262500_B21 2022061105054262500_B3 2022061105054262500_B28 2022061105054262500_B2 2022061105054262500_B29 2022061105054262500_B1 2022061105054262500_B26 2022061105054262500_B27 2022061105054262500_B7 2022061105054262500_B24 2022061105054262500_B6 2022061105054262500_B25 2022061105054262500_B5 2022061105054262500_B22 2022061105054262500_B4 2022061105054262500_B23 2022061105054262500_B9 2022061105054262500_B8 |
References_xml | – ident: 2022061105054262500_B15 doi: 10.1073/pnas.87.24.10028 – ident: 2022061105054262500_B8 – ident: 2022061105054262500_B16 doi: 10.1006/cbir.1997.0220 – ident: 2022061105054262500_B27 doi: 10.1016/S0021-9258(19)85312-7 – ident: 2022061105054262500_B14 doi: 10.1016/0022-1759(91)90327-C – ident: 2022061105054262500_B25 doi: 10.1158/1535-7163.1049.3.9 – ident: 2022061105054262500_B13 doi: 10.1038/35030140 – ident: 2022061105054262500_B24 doi: 10.1006/abbi.1998.0618 – ident: 2022061105054262500_B5 doi: 10.1038/sj.neo.7900218 – ident: 2022061105054262500_B12 doi: 10.1002/ijc.1565 – ident: 2022061105054262500_B7 – ident: 2022061105054262500_B17 doi: 10.1016/S0891-5849(03)00142-4 – ident: 2022061105054262500_B9 doi: 10.1177/1534735402238185 – ident: 2022061105054262500_B18 doi: 10.1073/pnas.1231994100 – ident: 2022061105054262500_B29 doi: 10.1016/S0024-3205(98)00560-8 – ident: 2022061105054262500_B1 doi: 10.1038/nm0195-27 – ident: 2022061105054262500_B20 doi: 10.1152/jappl.1993.74.3.1425 – ident: 2022061105054262500_B28 – ident: 2022061105054262500_B30 doi: 10.1074/jbc.M307146200 – ident: 2022061105054262500_B22 doi: 10.1038/sj.bjc.6600078 – ident: 2022061105054262500_B10 doi: 10.1016/0162-0134(84)85008-4 – ident: 2022061105054262500_B11 doi: 10.1016/0162-0134(86)80011-3 – ident: 2022061105054262500_B26 doi: 10.1074/jbc.M107711200 – ident: 2022061105054262500_B21 doi: 10.2174/1568009053765807 – ident: 2022061105054262500_B2 – ident: 2022061105054262500_B4 – ident: 2022061105054262500_B6 – ident: 2022061105054262500_B3 doi: 10.1016/0014-4827(80)90051-8 – ident: 2022061105054262500_B19 doi: 10.1073/pnas.89.21.10405 – ident: 2022061105054262500_B23 doi: 10.1161/01.RES.85.2.147 |
SSID | ssj0014104 |
Score | 2.2950296 |
Snippet | Purpose: A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with
high affinity, is currently... A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently... Abstract Purpose: A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is... PURPOSEA second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently... |
SourceID | proquest crossref pubmed pascalfrancis highwire |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 4974 |
SubjectTerms | Angiogenesis Inhibitors - pharmacology angiogenesis inhibitors: endogenous and synthetic Antineoplastic agents Apoptosis - drug effects Apoptosis - physiology Biological and medical sciences cell growth/signaling pathways Cell Proliferation - drug effects Copper - metabolism Endothelial Cells - drug effects Endothelial Cells - enzymology experimental and molecular therapeutics Humans Medical sciences Mitogen-Activated Protein Kinase 1 - metabolism Mitogen-Activated Protein Kinase 3 - metabolism Molybdenum - pharmacology Multiple Myeloma - blood supply Multiple Myeloma - drug therapy Multiple Myeloma - enzymology Multiple Myeloma - pathology new targets Pharmacology. Drug treatments Phosphorylation - drug effects signal transduction Superoxide Dismutase - antagonists & inhibitors Superoxide Dismutase - metabolism Superoxide Dismutase-1 |
Title | Copper Binding by Tetrathiomolybdate Attenuates Angiogenesis and Tumor Cell Proliferation through the Inhibition of Superoxide Dismutase 1 |
URI | http://clincancerres.aacrjournals.org/content/12/16/4974.abstract https://www.ncbi.nlm.nih.gov/pubmed/16914587 https://search.proquest.com/docview/68756237 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAviPvKZViIt6ilSZzbIxTQGBog2KS-WbbjrEFtUrWNxPgJ_Cf-G-fEzqVsk4CXtE1Uu833-eSc43Mh5MUkDZTnZ95IMEzJiZkcCeWDzSMCmSWhymSCucPHH8PDU3Y0C2aDwa9e1FK1lWP149K8kv9BFc4Brpgl-w_ItoPCCXgP-MIREIbjX2E8LVcrvXZkblJTUJPUWG12npfLcnEu0Zp3sIBmUaFK6YjiLC_PULrlpjTztlqWawed9xiotcAwF0OIpn0PqqV5Mc9l3miWmwpLi3_PU42bO0sM6daO29dxp02ypUJGrR1bT6j1Ox8BK43fGrcfOjftaw2KqoL_bbZHaip92ijRhg9_zsGuH32dY1yaicg3Pdm6oEcgfC1FZ7kov1XFny6NeGSSOq0UnmDZX2Ydn9pK5gCkoWcaS7Si2-tTtC-IWWKa_1x8QgRx7aywM4yn0y8m8st0gumxZrWsaYPVhFhgtYLd0tzNpWvkuhclAdr-b95_aDexmFt3r2znsglk8AteXjo_FrC1I-5qSU3lagzcFXDfF5lpunK1VVRrRye3yS1r1tBXhqN3yEAXd8mNYxu4cY_8NFSllqpUntOLVKUdVWmfqvAhpTVVKVKV7lCVWqrCq6YdVWmZ0Y6qtKUqde-T03dvT6aHI9sGZKRYnGxhxSeeSDPGtAqSONUqnkRZItxUaxYLnYEFoLTnA-Kom4Yy8dVEhZGIfCFcL4v8B2SvKAu9Tyg8b1yVKj9VIkV0pJvKxMMSiwwMmSgYknFz2_nKVHvhtZUcxBwh4wgZB8g4RoMCZEPyvAGHm0XVrCnuetwNOfJwSA52YOuGrvuJBJMhedbgyEG6460UhS6rDQ_jCA2UaEgeGni771qmPLryymNys1tcT8jedl3pp6BBb-VBzdPf6HDH9A |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Copper+binding+by+tetrathiomolybdate+attenuates+angiogenesis+and+tumor+cell+proliferation+through+the+inhibition+of+superoxide+dismutase+1&rft.jtitle=Clinical+cancer+research&rft.au=Juarez%2C+Jose+C&rft.au=Betancourt%2C+Jr%2C+Oscar&rft.au=Pirie-Shepherd%2C+Steven+R&rft.au=Guan%2C+Xiaojun&rft.date=2006-08-15&rft.issn=1078-0432&rft.eissn=1557-3265&rft.volume=12&rft.issue=16&rft.spage=4974&rft_id=info:doi/10.1158%2F1078-0432.CCR-06-0171&rft_id=info%3Apmid%2F16914587&rft.externalDocID=16914587 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |